Neuraxpharm Snapped Up By Private Equity In Europe’s Largest Deal
Under Control Of Apax Partners Since 2016
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
